At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)
In Brief
A Phase 2 clinical trial evaluating Ocriplasmin and Sham injection for Exudative Age-Related Macular Degeneration and Focal Vitreomacular Adhesion. Completed, enrolled 100 participants across 27 sites in 6 countries.
Detailed Summary
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).
Study Details
Timeline
Interventions
ocriplasmin intravitreal injection (125 µg)
Sham injection